LUCA Biologics develops living medicines targeting the vaginal microbiome using metagenomic and metatranscriptomic approaches to identify and validate therapeutic strains. Their pipeline addresses conditions such as urinary tract infections, bacterial vaginosis, and infertility, aiming to improve reproductive and urogenital health.
Funding
$2.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for urogenital and reproductive health conditions like urinary tract infections (UTIs), bacterial vaginosis (BV), and infertility often have limited effectiveness or undesirable side effects. Traditional approaches may not fully address the complex interplay between the host and the vaginal microbiome. There is a need for more targeted and sustainable therapies that restore microbial balance and promote long-term health.
Solution
LUCA Biologics is developing living medicines that target the vaginal microbiome to address a range of urogenital and reproductive health conditions. The company employs metagenomic and metatranscriptomic approaches to identify and validate therapeutic microbial strains. By analyzing microbial and host responses using computational biology and multiomics, LUCA Biologics aims to develop targeted interventions that restore microbial balance and improve patient outcomes. Their end-to-end platform spans discovery, development, clinical validation, and go-to-market strategies, ensuring a comprehensive approach to microbiome-based therapeutics.
Target Audience
The primary target audience includes women experiencing urogenital and reproductive health issues such as UTIs, bacterial vaginosis, infertility, and those seeking preventative care for cervical cancer.
Features
- Identification of therapeutic microbial strains using metagenomic and metatranscriptomic analysis
- Multi-omics approach to screen for unique and redundant microbial genes at the level of single nucleotide polymorphisms (SNPs)
- Prebiotic, probiotic, postbiotic, and synbiotic formulations
- Live biotherapeutics for cervical cancer prevention and recurrent UTIs
- Synbiotics and abiotics for vaginal health
- End-to-end platform encompassing discovery, development, clinical trials, and commercialization